Sorafenib: key lessons from over 10 years of experience

Area of Science:

• Oncology
• Pharmacology

Background:

• Sorafenib was the first targeted therapy for advanced renal cell carcinoma (RCC) in 2005.
• It was the sole systemic therapy demonstrating survival benefit in first-line unresectable hepatocellular carcinoma (HCC) for over a decade.
• In 2013, sorafenib became the first targeted agent for radioactive iodine-refractory differentiated thyroid cancer (DTC).

Purpose of the Study:

• This review examines the development, progress, and challenges of sorafenib in RCC, HCC, and DTC over the last decade.
• It synthesizes clinical and real-world data to enhance patient management and treatment efficacy.
• The review also touches upon ongoing clinical trials evaluating sorafenib's use in various settings and combinations.

Main Methods:

• A comprehensive literature search was conducted using PubMed and key congress proceedings.
• No time restrictions were applied to the search to ensure a thorough review.
• The review synthesizes existing data on sorafenib's efficacy, safety, and clinical application.

Main Results:

• Sorafenib has significantly impacted the therapeutic landscape for RCC, HCC, and DTC.
• Despite new treatments emerging, sorafenib continues to be an important therapeutic choice.
• Extensive clinical and real-world data have improved patient management and maximized treatment benefits.

Conclusions:

• Sorafenib has a lasting influence on the treatment of RCC, HCC, and DTC.
• Its continued evaluation in clinical trials suggests its enduring role in cancer therapy.
• Sorafenib is expected to remain a crucial treatment option in the foreseeable future.